Format

Send to

Choose Destination
Oncotarget. 2017 Oct 19;8(58):98723-98732. doi: 10.18632/oncotarget.21920. eCollection 2017 Nov 17.

Prognostic factors for histiocytic and dendritic cell neoplasms.

Author information

1
Department of Pathology, Kurume University, School of Medicine, Kurume, Japan.
2
Department of Hematology, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
3
Department of Hematology, Kurume University, School of Medicine, Kurume, Japan.

Abstract

Histiocytic and dendritic cell neoplasms are rare and poorly studied. We report the clinical characteristics and prognostic factors in such cases in Japan. We investigated the clinical characteristics and survival in 87 adult patients with histiocytic and dendritic cell neoplasms. Fifty patients had histiocytic sarcoma, 12 had Langerhans cell histiocytosis, 11 had follicular dendritic cell sarcoma, 8 had Langerhans cell sarcoma, 6 had interdigitating cell sarcoma and 1 had indeterminate dendritic cell sarcoma. The median follow-up period was 18.0 (range: 9.6-71.8) months, and median overall survival (OS) was 23.5 months. The 2-year OS rate was 49.2%. In the multivariate analysis, elevated lactate dehydrogenase (LDH) (p =.004), ECOG performance status (PS) 2-4 (p =.006), and Ann Arbor stage III-IV (p =.008) affected OS. Stratification by elevated LDH, ECOG PS 2-4, and Ann Arbor stage III-IV allowed classification of patients into low risk, intermediate risk, and high risk groups. The same classification was applicable for HS and non-HS categories. In the rare neoplasms of histiocytic and dendritic cell sarcoma, ECOG PS, Ann Arbor stage, and LDH are important prognostic factors for predicting survival.

KEYWORDS:

BRAF; dendritic cell neoplasm; histiocytic sarcoma; prognostic factor; survival

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center